Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts: Gene/Protein Disease Symptom Drug Enzyme Compound   Target Concepts: Gene/Protein Disease Symptom Drug Enzyme Compound

---

Query: EC:3.6.1.3 (ATPase)
65,361 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A highly tumorigenic subdiploid cell line, BP6T, derived in our laboratory from Syrian hamster embryo (SHE) cells, is amenable to studies of somatic mutation in vitro. Cellular and biochemical characterization of clonally derived BP6T cells resistant to 6-thioguanine (TGr) or ouabain (Quar) demonstrated these mutants to be similar qualitatively to mutants of SHE cells characterized previously (Barrett et al., 1978). BP6T TGr mutants resistant to 6-thioguanine are cross-resistant to 8-azaguanine, lack HPRT activity, exhibit a low frequency of reversion and arise spontaneously at a rate of approximately 5 X 10(-7) mutants per cell per generation. BP6T Ouar mutants were shown to be highly resistant to ouabain-mediated inhibition of 86Rb influx, indicating an alteration in the Na+/K+ ATPase. These studies on the BP6T cell line provide the experimental basis for a comparative study of the mutagenic responses of normal, diploid SHE cells versus those of related, but transformed aneuploid cells. Highly synchronized cultures of these 2 cells were mutagenized by pulse treatment with BrdU during different periods of S phase, followed immediately by near-UV irradiation. The induced mutation frequencies so obtained provided information about the temporal order of replication of genes encoding HPRT and Na+/K+ ATPase in both SHE and BP6T cells. The temporal pattern of replication of Na+/K+ ATPase gene loci is similar in both cell types, but the temporal order of replication of the HPRT gene is significantly different between SHE and BP6T cells (mid-late S phase, versus early S phase, resp.). This observed difference emphasizes the caution required in the study of mutagenesis and DNA replication using transformed, aneuploid cells under the assumption that the underlying mechanisms are the same for normal, diploid cells.
...
PMID:Comparison between mutagenesis in normal and transformed Syrian hamster fibroblasts: difference in the temporal order of HPRT gene replication. 625 20

We have used liposomes to deliver DNAase I inside normal Syrian hamster embryo (SHE) cells. We showed the entrance of DNAase I inside the cell by dose-dependent cytotoxicity; and the entrance of DNAase I into the nucleus by the induction of chromosomal aberrations and somatic mutation at the HPRT locus (but not at the Na+/K+ ATPase locus). The induction of neoplastic transformation in cultures treated by DNAase I-in-liposomes was manifested by increased saturation density, colony formation at low seeding density, colony formation in 1% serum and 0.3% agar, and tumorigenicity in 100% of injected animals. The acquisition of anchorage-independent growth became apparent only after 39-57 posttreatment population doublings. Thus damage to DNA alone can initiate the neoplastic transformation process; but for full expression of the neoplastic phenotypes, a long progression time is required for the acquisition of anchorage-independent growth and tumorigenicity.
...
PMID:DNAase I encapsulated in liposomes can induce neoplastic transformation of Syrian hamster embryo cells in culture. 650 50

Two nitroxyl spin label (NSL) compounds that are used experimentally as in vivo contrast enhancers in magnetic resonance (MR) imaging were tested for acute toxicity in rats and for genotoxic effects in cell cultures. These compounds, 2,2,5,5-tetramethyl-1-pyrrolidinyl-oxy-3-carboxylic acid (PCA) and 2,2,6,6-tetramethyl-1-oxido-4-piperidinyl-1-succinic acid (TES) and their hydroxylamine and amine derivatives did not induce sister chromatid exchanges or mutations in Chinese hamster ovary cells at the HGPRT or Na+/K+ ATPase loci. The acute LD50 doses in rats for PCA and TES are 15.1 mmol/kg or greater, suggesting relatively high tolerance.
...
PMID:Nitroxyl spin label contrast enhancers for magnetic resonance imaging. Studies of acute toxicity and mutagenesis. 651 Dec 62

Chemical mutagenesis in animal cells is a complex process. Whereas some chemicals are mutagenic in their original form, others such as the nitrosamines and polycyclic hydrocarbon carcinogens are mutagenic only when enzymatically activated. The active form, or ultimate carcinogen, can interact with proteins and nucleic acids, altering amino acids and producing modified bases in DNA. The modified bases do not usually constitute mutations as produced. Instead they are acted on by the DNA enzymes of the cell, which repair most damaged bases but occasionally insert incorrect base sequences at or near the sites of damage. The frequency at which mutant animal cells are recovered depends upon the selection conditions in culture, upon whether the mutation selected is in a gene present in single or multiple active copies, and upon whether expression is dominant or recessive. Many studies depend on selecting for 8-azaguanine- or 6-thioguanine-resistant mutants, which are due to mutations in the HGPRT locus present in a single active copy on the X-chromosome. Other widely used systems depend on selecting for ouabain resistance, which is dominant and results from a change in the sodium/potassium ATPase activity, or on selecting for thymidine kinase mutants in heterozygous Tk+/Tk- mouse cells. Many other types of mutation including nutritional markers are recessive and express only in cells carrying a single active gene copy, as is sometimes the case in established cell lines. The types of base damage causing mutations have been identified in very few cases only, and little is known about the enzymatic mechanisms of mutagenesis. However, chemical mutagenesis in cultured animal cells provide a practical way of testing chemicals and radiations for mutagenicity directly in animal cells, and much has been learned about the mutagenicity of various carcinogenic substances. To date, there is reasonable qualitative agreement between these results and those obtained in the widely used liver microsome-activated bacterial mutagenesis test systems.
...
PMID:International Commission for Protection against Environmental Mutagens and Carcinogens. ICPEMC working paper 2/5: mutagenesis in mammalian cells. 702 63

As part of the International Workshop on Standardization of Genotoxicity Test Procedures, in Melbourne, 27-28 February 1993, various international guidelines were examined with respect to protocol issues in the area of mammalian cell gene mutation assays. The working group on mammalian cell gene mutation assays discussed a wide range of protocol issues related to study design; in most cases the recommendations are reasonably consistent with existing guidelines. Agreement was reached on several issues as follows. The upper limit of concentration for testing non-toxic substances should be 10 mM or 5 mg/ml, whichever is lower. For testing toxic substances the criteria of an acceptable upper limit of concentration should yield 10-20% survival. Any of several established mammalian cell mutation assays (L5178Y TK+/-, CHO/HPRT, AS52/XPRT, V79/HPRT) can be used to evaluate mutagenesis in mammalian cells; the ouabain (Na/K-ATPase) system is not an acceptable mutation assay for routine evaluation of mutagenesis in mammalian cells. Ability to recover small colonies must be convincingly demonstrated when using the L5178Y TK+/- mouse lymphoma assay. In the mouse lymphoma assay (L5178Y TK+/-), colonies in positive controls and at least two (if available) representative positive doses of the test compound should be sized if a positive response is seen; in the event of a negative response due to the test compound, colony sizing of the positive control is necessary to validate the conduct of the assay. Testing both in the presence and absence of S9 metabolic activation is necessary. It was not possible to come to a firm conclusion about the length of treatment. There was a general agreement that extended treatment times (> 2 cell cycles) often bear more disadvantages than advantages and should only be used with adequate justification. It is not necessary to repeat clear positive or clear negative tests when the assay has been adequately performed; this recommendation differs significantly from the UK guidelines. If treatment groups are not replicated, the numbers of doses tested should be increased; this recommendation differs significantly from the UK guidelines. Each laboratory should establish a historical database for the performance of a given assay in that laboratory.
...
PMID:Mammalian cell gene mutation assays working group report. 751 37

The genotoxic effects induced by the monofunctional nitrosourea derivative streptozotocin (STZ) were investigated in Chinese hamster ovary cells, parental (CHO-9) and its mutant hypersensitive to alkylating agents, designated EM-C11. The ability of this compound to induce chromosomal aberrations, cell killing, sister-chromatid exchanges (SCEs) and mutations was evaluated on these two cell lines. The mutant cells were found to be slightly more sensitive to the killing effects of STZ than the parental cell line. EM-C11 cells also showed higher levels of STZ-induced chromosomal aberrations than CHO-9 cells, but appeared to be equally sensitive to induction of SCEs. The frequencies of STZ-induced mutations, measured as resistant Na+/K(+)-ATPase and HPRT mutants, revealed a higher sensitivity of EM-C11 to the mutagenic effects of this compound.
...
PMID:Streptozotocin-induced chromosomal aberrations, SCEs and mutations in CHO-9 parental cells and in EM-C11 mutant cell line. 752 88

Testosterone, testosterone propionate, 17 beta-trenbolone and progesterone, which represent the main endogenous and synthetic androgens and a progestin, were evaluated for possible cell transformation and genetic effects in Syrian hamster embryo (SHE) cells. Cell growth was reduced by treatment with the steroids at 10-30 micrograms/ml in a dose-related manner. Testosterone and testosterone propionate were less toxic than the other two steroids. Testosterone, testosterone propionate and progesterone induced morphological transformation of SHE cells with similar transformation frequencies. The most potent effects were observed with testosterone propionate, which induced cell transformation at 1-30 micrograms/ml in a dose-related manner. Testosterone and progesterone transformed cells only at the highest dose (30 micrograms/ml). 17 beta-Trenbolone did not induce a statistically significant level of cell transformations at any dose tested (up to 30 micrograms/ml). The transformation frequencies induced by testosterone, testosterone propionate and progesterone were less than one-half that induced by benzo[a]pyrene at 1 microgram/ml. None of these steroids induced significant increases in frequencies of chromosome aberrations or aneuploidy. Gene mutations were not observed for testosterone at the HPRT or Na+/K+ ATPase locus. Because these steroids are also associated with carcinogenic activity in vivo, these in vitro findings provide a model and new insights into the study of the mechanisms of androgen- and progestin-induced cell transformation.
...
PMID:Effects of testosterone, testosterone propionate, 17 beta-trenbolone and progesterone on cell transformation and mutagenesis in Syrian hamster embryo cells. 778 50

The JAK2(V617F) mutation is frequently observed in classical myeloproliferative disorders, and disease progression is associated with a biallelic acquisition of the mutation occurring by mitotic recombination. In this study, we examined whether JAK2 activation could lead to increased homologous recombination (HR) and genetic instability. In a Ba/F3 cell line expressing the erythropoietin (EPO) receptor, mutant JAK2(V617F) and, to a lesser extent, wild-type (wt) JAK2 induced an increase in HR activity in the presence of EPO without modifying nonhomologous end-joining efficiency. Moreover, a marked augmentation in HR activity was found in CD34(+)-derived cells isolated from patients with polycythemia vera or primitive myelofibrosis compared with control samples. This increase was associated with a spontaneous RAD51 foci formation. As a result, sister chromatid exchange was 50% augmented in JAK2(V617F) Ba/F3 cells compared with JAK2wt cells. Moreover, JAK2 activation increased centrosome and ploidy abnormalities. Finally, in JAK2(V617F) Ba/F3 cells, we found a 100-fold and 10-fold increase in mutagenesis at the HPRT and Na/K ATPase loci, respectively. Together, this work highlights a new molecular mechanism for HR regulation mediated by JAK2 and more efficiently by JAK2(V617F). Our study might provide some keys to understand how a single mutation can give rise to different pathologies.
...
PMID:JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders. 1851 59


<< Previous 1 2

---